Get the Stockscreener App
4.87
1.62%
-0.08
Aldeyra Therapeutics Inc stock is traded at $4.87, with a volume of 237.81K.
It is down -1.62% in the last 24 hours and down -7.41% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$4.95
Open:
$4.95
24h Volume:
237.81K
Relative Volume:
0.33
Market Cap:
$297.81M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-6.4933
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
-6.88%
1M Performance:
-7.41%
6M Performance:
+125.46%
1Y Performance:
+3.62%
1-Day Range:
$4.795
$4.99
1-Week Range:
$4.795
$5.35
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
4.865 | 297.81M | 0 | -44.80M | -30.67M | -0.75 |
|
ARGX
Argen X Se Adr
|
913.17 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.09 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
198.87 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
361.00 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.92 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Live market analysis of Aldeyra Therapeutics Inc.Treasury Yields & Fast Gaining Stock Reports - newser.com
Aldeyra Therapeutics Inc. stock daily chart insightsFed Meeting & Safe Capital Growth Stock Tips - newser.com
Why Aldeyra Therapeutics Inc. stock is in analyst buy zone2025 Price Action Summary & Low Drawdown Trading Strategies - newser.com
Sentiment analysis tools applied to Aldeyra Therapeutics Inc.July 2025 Recap & Weekly Market Pulse Alerts - newser.com
Smart tools for monitoring Aldeyra Therapeutics Inc.’s price actionWeekly Trading Summary & AI Forecast Swing Trade Picks - newser.com
Applying Wyckoff theory to Aldeyra Therapeutics Inc. stock2025 AllTime Highs & Growth Focused Entry Reports - newser.com
Aldeyra Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Closing Moves & Low Risk Investment Opportunities - newser.com
What to expect from Aldeyra Therapeutics Inc. in the next 30 daysTrade Ideas & Weekly Top Gainers Trade List - newser.com
How Aldeyra Therapeutics Inc. stock performs in weak economyMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
Intraday pattern recognizer results for Aldeyra Therapeutics Inc.2025 Price Targets & Smart Money Movement Alerts - newser.com
Can a trend reversal in Aldeyra Therapeutics Inc. lead to recoveryLayoff News & Stock Timing and Entry Methods - newser.com
Is Aldeyra Therapeutics Inc. stock resilient to inflation2025 Market Sentiment & Accurate Intraday Trade Tips - Fundação Cultural do Pará
Is Aldeyra Therapeutics Inc. stock dividend yield sustainableQuarterly Market Summary & Pattern Based Trade Signal System - Fundação Cultural do Pará
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research and Development Webcast - MarketScreener
Is Aldeyra Therapeutics Inc. stock affected by interest rate hikesPortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
Aldeyra expands RASP platform to include neuroinflammatory diseases By Investing.com - Investing.com Nigeria
Understanding Aldeyra Therapeutics Inc.’s price movementQuarterly Performance Summary & Consistent Return Investment Signals - newser.com
Automated trading signals detected on Aldeyra Therapeutics Inc.Dip Buying & Stepwise Trade Execution Plans - newser.com
Analyzing net buyer seller activity in Aldeyra Therapeutics Inc.Risk Management & Real-Time Buy Signal Alerts - newser.com
ALDX: ADX-248 advances in CNS and immune diseases as reproxalap nears FDA approval, with strong financials - TradingView
Published on: 2025-11-13 12:25:09 - newser.com
Aldeyra (ALDX) Expands RASP Platform to Target Neuroinflammatory Diseases - GuruFocus
Aldeyra Therapeutics announces expansion of rasp platform - MarketScreener
Aldeyra expands RASP platform to include neuroinflammatory diseases - Investing.com India
Aldeyra Therapeutics Expands RASP Platform and Updates on Reproxalap - TradingView
Key FDA Verdict Looms for Aldeyra’s Lead Drug Candidate - AD HOC NEWS
Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI - Stock Titan
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):